CLV

Clinuvel Pharmaceuticals ADR

Stock
Stock
Ticker: CLVLY
CLVLY

Price

Price

CHART BY

Historical dividends and forecast

Clinuvel Pharmaceuticals ADR has so far distributed $0.0356 in 2026. 


$0.0286

CHART BY

Frequently asked questions

The market capitalization of Clinuvel Pharmaceuticals ADR is $253.19M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
The Price-to-Earnings (P/E) ratio (TTM) for Clinuvel Pharmaceuticals ADR is 10.91. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.
Clinuvel Pharmaceuticals ADR's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $0.464. EPS indicates the company's profitability on a per-share basis.
Currently, 7 analysts cover Clinuvel Pharmaceuticals ADR's stock, with a consensus target price of $11.80. Analyst ratings provide insights into the stock's expected performance.
Over the trailing twelve months, Clinuvel Pharmaceuticals ADR reported a revenue of $64.31M.
Clinuvel Pharmaceuticals ADR's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $28.63M. EBITDA measures the company's overall financial performance.
Clinuvel Pharmaceuticals ADR has a free cash flow of $24.81M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

Financials

Market Cap 
$253.19M
EPS (TTM) 
$0.464
P/E ratio (TTM) 
10.91
Revenue (TTM) 
$64.31M
EBITDA (TTM) 
$28.63M
Free Cashflow (TTM) 
$24.81M

Pricing

1D span
$4.892$5.165
52W span
$4.81$8.12

Analyst Ratings

The price target is $11.80 and the stock is covered by 7 analysts.

Buy

4

Hold

2

Sell

1

Information

Clinuvel Pharmaceuticals Ltd. operates as a biopharmaceutical company. The firm engages in the development of SCENESSE, its proprietary photoprotective drug. It also offers drugs for the treatment of various skin disorders. The company was founded by Robert Thomas Dorr on December 14, 1999 and is headquartered in Melbourne, Australia.

Industries
Major Pharmaceuticals
Sector
Health Care

Identifier

Primary Ticker
CLVLY

Knockouts

Real-time data from LSX · Fundamentals & EOD data from FactSet
Join the conversation